A son of glembatumumab vedotin has just started its phase 1 study.
ApexOnco Front Page
Recent articles
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
Three private biotechs enter clinical trials, one targeting KRAS.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
Readout of the Pivot-006 trial is brought forward by nearly a year.
The company secures funding to push its lead candidate towards US approval.
Prexasertib data worsen again, and biomarkers are up in the air.
